PIK3CA and breast carcinoma: Strikingly, only 4.4% of M0-stage patients harbored PIK3CA mutations, whereas manifest HR+ breast cancer patients with metastasis displayed them in 34.3% of cases (Fisher’s exact test, p < 0.0001; Fig. 7d).